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http://dx.doi.org/10.1016/j.ccr.2013.05.002SUMMARYB cell receptor (BCR) signaling pathway components represent promising treatment targets in diffuse large
B cell lymphoma (DLBCL) and additional B cell tumors. BCR signaling activates spleen tyrosine kinase (SYK)
and downstream pathways including PI3K/AKT and NF-kB. In previous studies, chemical SYK blockade
selectively decreased BCR signaling and induced apoptosis of BCR-dependent DLBCLs. Herein, we charac-
terize distinct SYK/PI3K-dependent survival pathways in DLBCLs with high or low baseline NF-kB activity
including selective repression of the pro-apoptotic HRK protein in NF-kB-low tumors. We also define SYK/
PI3K-dependent cholesterol biosynthesis as a feed-forward mechanism of maintaining the integrity of
BCRs in lipid rafts in DLBCLs with low or high NF-kB. In addition, SYK amplification and PTEN deletion
are identified as selective genetic alterations in primary ‘‘BCR’’-type DLBCLs.INTRODUCTION
Several lines of evidence support the role of B cell receptor
(BCR)-mediated survival signals in certain B cell malignancies
(Chen et al., 2008; Gupta and DeFranco, 2007; Ku¨ppers, 2005;
Young et al., 2009). The BCR complex includes membrane-
bound immunoglobulin and the disulfide-linked heterodimer,
immunoglobulin-a (Iga) and Igb (also termed CD79A and
CD79B, respectively). BCR signaling induces receptor oligomer-Significance
Chemical inhibitors of SYK and additional proximal BCR pathw
and additional B cell malignancies. However, the BCR-depend
ponents such as SYK and PI3K and distal NF-kB signaling rem
apoptotic, and metabolic pathways perturbed by chemical inh
tional genetic bases for enhanced BCR signaling in DLBCLs
dependent DLBCLs and provide a framework for analyzing
components of the BCR signaling pathway in these tumors.
826 Cancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc.ization and phosphorylation of Iga and Igb immunoreceptor tyro-
sine-based activation motifs (ITAMS) by Src family kinases.
Following ITAM phosphorylation, the spleen tyrosine kinase
(SYK) is recruited and activated, engaging additional adaptor
proteins and initiating downstream signaling through phosphati-
dylinositol-3-kinase (PI3K), NF-kB, extracellular signal-related
kinase (ERK)-mitogen-activated protein kinase (MAPK), and
NFAT pathways. After ligand binding, BCRs cluster and rapidly
associate with cholesterol-enriched membrane microdomainsay components are in clinical trials in patients with DLBCL
ent survival pathways and respective roles of proximal com-
ain to be defined. We delineate the downstream signaling,
ibition or molecular depletion of SYK/PI3K and identify addi-
. These functional and genetic studies further define BCR-
targeted inhibition of SYK, PI3K, and additional proximal
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SYK/PI3K-Dependent Survival Pathways in DLBCLtermed lipid rafts (Dykstra et al., 2003; Gupta and DeFranco,
2007). SYK is recruited to BCR clusters associatedwith lipid rafts
and protein tyrosine phosphorylation is enhanced in these
regions (Gupta and DeFranco, 2007).
In addition to ligand-induced receptor aggregation and activa-
tion, normal mature B cells rely upon ‘‘tonic’’ BCR-dependent
survival signals (Kraus et al., 2004; Monroe, 2006; Srinivasan
et al., 2009; Torres et al., 1996). Tonic BCR signaling was initially
defined in murine models in which BCR ablation or Igamutation
triggered the apoptosis of normal mature B cells (Kraus et al.,
2004; Lam et al., 1997). In follow-up studies, BCR ablation was
combined with activation of specific BCR-dependent signaling
cascades to delineate the nature of tonic BCR survival signals
(Srinivasan et al., 2009). PI3K/AKT signaling, but not NF-kB or
MAPK kinase activation, rescued the survival of BCR-deficient
B cells (Srinivasan et al., 2009). These studies defined important
differences between PI3K/AKT-dependent tonic BCR survival
signals and those resulting from activation of additional down-
stream pathways following BCR engagement (Srinivasan et al.,
2009).
Diffuse large B cell lymphomas (DLBCLs) are clinically and
genetically heterogeneous disorders in which subsets of tumors
share certain molecular features. In the cell-of-origin (COO) clas-
sification, groups of DLBCLs share components of their tran-
scriptional profiles with normal B cell subtypes, including
germinal center B cells (GC) and activated B cells (ABC) (Wright
et al., 2003). In comparison to GC DLBCLs, ABC tumors more
frequently exhibit constitutive activation of NF-kB and genetic
alterations of several NF-kB pathway components (Compagno
et al., 2009; Davis et al., 2001; Rosenwald et al., 2002). This
group of DLBCLs is also reported to have more frequent somatic
mutations of the Iga or Igb subunits and altered BCR surface
expression, a process termed ‘‘chronic active BCR signaling’’
(Davis et al., 2010). Certain BCR-dependent ‘‘ABC’’ DLBCL cell
lines also exhibit constitutive PI3K activation, which modulates
downstream NF-kB signaling (Kloo et al., 2011).
Using an alternative approach to define DLBCLs with shared
molecular features, we previously applied consensus clustering
methods to the transcriptional profiles of primary DLBCLs and
identified three highly reproducible tumor groups: BCR, OxPhos
(oxidative phosphorylation), and HR (host response) (Monti et al.,
2005). ‘‘BCR’’ DLBCLs had increased expression of multiple
components of the BCR signaling pathway including SYK (Monti
et al., 2005) prompting speculation that these lymphomas relied
upon SYK/BCR-mediated survival signals (Chen et al., 2008).
This hypothesis was of additional interest given the known role
of SYK in tonic BCR signaling (Monroe, 2006) and malignant
B cell survival (Chen et al., 2006).
For these reasons, we previously assessed the in vitro efficacy
of an ATP-competitive inhibitor of SYK525/526 phosphorylation
and activation, R406, in DLBCL cell lines and primary tumors
(Chen et al., 2008). Chemical SYK blockade selectively
decreased the proliferation and induced apoptosis of surface
sIg+ DLBCL cell lines with intact BCR signaling (Chen et al.,
2008). In R406-sensitive DLBCL cell lines, the compound specif-
ically inhibited both baseline- and ligand-induced autophos-
phorylation of SYK525/526 and SYK-dependent phosphoryla-
tion of BCR signaling components such as B cell linker protein
BLNK (Chen et al., 2008). The majority of examined sIg+ primaryDLBCLs also exhibited baseline and ligand-induced BCR activ-
ity. In these primary tumors, BCR signaling, as reflected by intra-
cellular phospho-BLNK (p-BLNK) expression, was also inhibited
by R406 (Chen et al., 2008).
We subsequently performed a clinical trial of the oral SYK
inhibitor, fostamatinib (R788), of which R406 is a prodrug, in
patients with recurrent B cell non-Hodgkin lymphoma (B-NHL)
and found that 22% of patients with DLBCL and 50% of patients
with small lymphocytic lymphoma/chronic lymphocytic leukemia
responded to treatment (Friedberg et al., 2010). Other investiga-
tors also demonstrated the efficacy of chemical inhibition or
molecular depletion of SYK in BCR-dependent DLBCL cell lines
and in vivo murine lymphomamodels (Cheng et al., 2011; Rinaldi
et al., 2011; Young et al., 2009). We also recently defined
distinct fuel utilization programs in BCR-dependent and BCR-
independent/OxPhos DLBCLs (Caro et al., 2012).
Although BCR signaling is an attractive rational therapeutic
target and chemical inhibitors of SYK and additional proximal
BCR-pathway components have demonstrated efficacy in early
clinical trials (Friedberg et al., 2010; Hendriks, 2011; Herman
et al., 2011; Lannutti et al., 2011; Robertson et al., 2007),
subtype-specific effector pathways and underlying genetic
mechanisms are incompletely understood. In addition, the
consequences of inhibiting BCR signaling in tumors assigned
to different transcriptional subtypes require further definition.
Herein, we characterize the downstream signaling, apoptotic,
and metabolic pathways altered by chemical or molecular SYK
inhibition and identify additional genetic bases for enhanced
BCR signaling in DLBCLs.
RESULTS
SYK Depletion Selectively Inhibits the Proliferation
of BCR-Dependent DLBCL Cell Lines
To further characterize SYK as a potential target, we depleted
SYK with multiple independent shRNAs, then assessed cellular
proliferation in a panel of DLBCL cell lines that captured known
functional distinctions: BCR dependence versus independence
and ABC versus GC transcriptional subtype. The panel included
BCR-dependent/GC lines (DHL4 and LY7), BCR-dependent/
ABC lines (HBL-1 and U-2932), and BCR-independent lines
(K422 and LY4, otherwise classified as ‘‘OxPhos’’) (Caro et al.,
2012; Chen et al., 2008; Figures S1A–S1E available online).
SYK knockdown significantly decreased the proliferation of all
BCR-dependent lines but had little effect on the growth of
BCR-independent lines (Figures 1A and 1B; Figure S1F). The
selectivity of molecular SYK depletion for BCR-dependent
DLBCLs closely mirrors that of the chemical SYK inhibitor,
R406 (Figure 1B; Figures S1D–S1F; Chen et al., 2008).
SYK- and PI3K-Dependent BCR Signaling in DLBCLs
with High Baseline NF-kB
A subset of DLBCL primary tumors and cell lines exhibits high
baseline NF-kB activity and multiple genetic alterations of
NF-kB pathway components (Compagno et al., 2009; Davis
et al., 2001; Lenz et al., 2008). We therefore characterized
signaling pathways affected by SYK inhibition in DLBCLs with
high versus low baseline NF-kB activity. First, we assessed the
baseline NF-kB activity in a panel of eight DLBCL cell lines,Cancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc. 827
Figure 1. Cellular Proliferation of DLBCL Cell Lines following SYK
Depletion
(A) The SYK protein level in cell lysates prepared from the indicated cell lines
transduced with a negative control (NC) shRNA or the indicated SYK shRNAs
was assessed by immunoblotting. b-actin, loading control.
(B) Cellular proliferation of SYK-depleted DLBCL cell lines wasmeasured 72 hr
after puromycin selection by MTS assay. The proliferation of SYK-depleted
cells is relative to that of NC cells. Error bars represent SD of three independent
assays from a representative experiment. The p values for NC versus
each SYK shRNA were determined with a one-sided Welch t test. ***p %
0.0001; **p% 0.001.
See also Figure S1.
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SYK/PI3K-Dependent Survival Pathways in DLBCLincluding the six used above and an additional BCR-depend-
ent/GC line (DHL6) and another BCR-independent (Toledo) line
(Chen et al., 2008; Caro et al., 2012). As expected, baseline
NF-kB activity was higher in the BCR-dependent/ABC lines
than in the BCR-dependent/GC lines (Figure 2A; Davis et al.,
2001). R406 treatment significantly decreased the high baseline
NF-kB activity in HBL-1 and U-2932 and also reduced the low
baseline activity in DHL4, DHL6, and LY7, but had no effect on
the BCR-independent lines (Figure 2A).
To further characterize the consequences of chemical SYK
inhibition in the BCR-dependent DLBCL cell lines with high or
low baseline NF-kB activity, we performed transcriptional
profiling of all five lines at baseline and following 6 and 24 hr
treatment with R406 or DMSO (vehicle). At each time point, the
genes that were differentially expressed between the vehicle
and R406-treated samples (FDR-corrected q-values % 0.01
and fold changes R 1.53 ) were analyzed for pathway enrich-
ment (Figures S2A–S2C; Table S1).
In contrast to the NF-kB-low lines, NF-kB-high lines exhibited
significant downregulation of TNF, TNFR2, NF-kB, CD40, and
RELA pathway components including multiple common NF-kB
target genes (Figures S2B and S2C; Table S1). Independently,
we also performed gene set enrichment analysis (GSEA) of
vehicle- versus R406-treated cell lines using functionally defined
series of NF-kB target genes (Davis et al., 2010; Schreiber et al.,
2006). With this approach, we identified statistically significant,
concordant downregulation of multiple functionally validated828 Cancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc.NF-kB target genes in the NF-kB-high DLBCL cell lines following
R406 treatment (Figures 2B and 2C). In contrast, GSEA revealed
no significant modulation of NF-kB target gene sets in the
NF-kB-low DLBCL cell lines (data not shown). We further
assessed the transcript abundance of 4 of these NF-kB targets
(BCL2A1 [also known as BFL-1/A1], TNF, CD40, and TRAF1;
Figure 2C) in the full series of eight DLBCL lines treated with
vehicle or R406 using qRT-PCR. All four NF-kB targets were
selectively and significantly downregulated in the BCR-depen-
dent NF-kB-high DLBCL cell lines (Figure 2D; Figure S2D).
Given the demonstrated role of the NF-kB target, BCL2A1, in
B cell survival and resistance to apoptosis (Lee et al., 1999;
Ottina et al., 2012; Zong et al., 1999), we also evaluated
BCL2A1 protein expression in DLBCLs treated with vehicle or
R406. The two BCR-dependent NF-kB-high lines, HBL-1 and
U-2932, had abundant baseline BCL2A1 protein expression
that decreased following R406 treatment whereas BCR-depen-
dent NF-kB-low lines (DHL4, DHL6, and LY7) and BCR-indepen-
dent lines (K422, Toledo, and LY4) had much lower BCL2A1
expression (Figure 2E).We also depleted SYKwithmultiple inde-
pendent shRNAs and evaluated BCL2A1 transcript abundance
in two BCR-dependent NF-kB-high DLBCL lines (HBL-1 and
U-2932) and a BCR-dependent NF-kB-low line (DHL4). SYK
knockdown significantly decreased BCL2A1 transcript abun-
dance in the NF-kB-high lines and also reduced the modest
BCL2A1 expression in the NF-kB-low line (Figure 2F).
Given the recently described role of PI3K signaling in modu-
lating NF-kB activity in certain DLBCL cell lines (Kloo et al.,
2011), we next treated BCR-dependent lines with PI3K inhibitor,
LY294002, and evaluated NF-kB activity and BCL2A1 expres-
sion. In DLBCL cell lines with high baseline NF-kB (HBL-1 and
U-2932), PI3K inhibition significantly decreased NF-kB activity
and BCL2A1 abundance (Figures 2G and 2H). Together, these
data confirm that NF-kB activity is modulated by BCR-depen-
dent SYK and PI3K signaling in certain ‘‘ABC’’ DLBCL cell lines.
SYK- and PI3K-Dependent BCR Signaling in DLBCLs
with Low Baseline NF-kB
Previous murine models of tonic BCR signaling implicated PI3K/
AKT activation and FOXO1 modulation in normal B cell survival,
independent of NF-kB (Srinivasan et al., 2009). These data
prompted us to evaluate the role of PI3K/AKT in BCR-dependent
DLBCLs with low baseline NF-kB activity.
Representative BCR-dependent DLBCL cell lines with low
baseline NF-kB activity, DHL4, DHL6 and LY7, were infected
with either a pMIG empty vector or the pMIG-mAKT1-IRES-
GFP (mAKT) vector which encodes constitutively active AKT1.
GFP+ cells were sorted by flow cytometry, treated with R406
or vehicle control and analyzed for p-AKT expression and cellular
proliferation. All three BCR-dependent DLBCL cell lines infected
with the control pMIG vector exhibited baseline AKT phosphor-
ylation that was inhibited by R406 (Figure 3A). As expected,
expression of mAKT increased the level of p-AKT, which was
not significantly affected by R406 (Figure 3A). Expression of
mAKT largely protected these BCR-dependent DLBCLs from
chemical SYK inhibition (Figure 3B). Although mAKT may signal
to a larger series of targets than endogenous AKT, these studies
nonetheless highlight the role of PI3K/AKT in SYK-dependent
survival signals.
Figure 2. SYK- and PI3K-Dependent BCR Signaling in DLBCLs with High Baseline NF-kB
(A) NF-kB (p65) activity was determined in vehicle and R406-treated DLBCL cell lines. Pos. Ctrl., manufacturer’s positive control. BCR-dependent NF-kB-low
lines, purple; BCR-dependent NF-kB-high lines, blue; BCR-independent OxPhos lines, green.
(B) GSEA of NF-kB targets was performed in vehicle- versus R406-treated DLBCL cell lines with high-baseline NF-kB activity (HBL-1 andU-2932). The 19K genes
in the genome were sorted from highest (left, red) to lowest (right, blue) relative expression in vehicle- versus R406-treated lines (horizontal axis). Note that the
positions of the NF-kB targets (set #1, Davis et al., 2010; and set #2, Schreiber et al., 2006) were significantly skewed toward the right end of the sorted list,
reflecting their statistically significant downregulation in R406-treated lines.
(C) Relative abundance of NF-kB target genes in vehicle- versus R406-treated DLBCL cell lines with high baseline NF-kB activity was displayed with a colometric
scale. NF-kB target genes derived from the GSEA leading edge, set #1 (Davis et al., 2010).
(D) BCL2A1 transcript abundance in DLBCL cell lines treated with vehicle or R406 (24 hr) was determined by qRT-PCR relative to PPIA.
(E) BCL2A1 protein abundance in vehicle- and R406-treated DLBCL cell lines was assessed by immunoblotting. b-actin, loading control.
(F) BCL2A1 transcript abundance in SYK-depleted DLBCL cell lines (72 hr following completion of puromycin selection) was determined by qRT-PCR relative
to PPIA.
(G) NF-kB (p65) activity was determined in DLBCL cell lines treated with the PI3K inhibitor LY294002 or vehicle.
(H) BCL2A1 transcript abundance in DLBCL cell lines treated with LY294002, R406, or vehicle (24 hr) was assessed by qRT-PCR relative to PPIA.
In (A), (D), and (F)–(H), p values for control versus treated were determined with a one-sidedWelch t test. ***p < 0.0001; **p < 0.001; *p < 0.01. Error bars represent
the SD of three independent assays in a representative experiment.
See also Figure S2 and Table S1.
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SYK/PI3K-Dependent Survival Pathways in DLBCLPI3K/AKT signaling phosphorylates the FOXO1 transcription
factor resulting in its nuclear exclusion and degradation and
decreased FOXO1 activity (Fu and Tindall, 2008; Srinivasan
et al., 2009). Given the role of PI3K/AKT in mediating SYK/BCR
survival signals, we assessed nuclear FOXO1 expression inR406-treated BCR-dependent DLBCLs. In addition to directly
visualizing FOXO1 by immunofluorescence (Figure 3C, left),
nuclear FOXO1 staining was quantified (Figure 3C, right). In
each of the BCR-dependent DLBCL cell lines, chemical SYK/
BCR inhibition significantly increased the nuclear localization ofCancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc. 829
Figure 3. SYK and PI3K-Dependent Signaling in DLBCLs with Low Baseline NF-kB
(A and B) DHL4, DHL6, and LY7 cell lines were retrovirally transduced with mAKT or pMIG vector, FACS-sorted for GFP expression, treated for 24 hr with R406 or
vehicle, then analyzed for p-AKT(S473) and total AKT by immunoblotting (A) and for proliferation (B).
(C) DLBCL cell lines were incubated with R406 or vehicle for 1 hr, BCR cross-linked (BCR) or left untreated, fixed, then stained with DAPI (blue) and with
Cy3-conjugated anti-FOXO1 antibody (red) (left). Scale bar represents 10 mm. The mean nuclear staining intensity of Cy3-conjugated-FOXO1 was quantified for
each cell and plotted against its mean DAPI staining intensity (right).
(D) The transcript abundance of FOXO1 target genes, p27 and BIM, in DLBCL cell lines treatedwith R406 or vehicle for 24 hr was assessed by qRT-PCR relative to
PPIA. The p values for mAKT versus pMIG (control) at each time point (B) and for vehicle versus R406 (D) were determined with a one-sided Welch t test. ***p%
0.0001; **p% 0.001. Error bars represent the SD of three independent assays in a representative experiment.
See also Figure S3.
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SYK/PI3K-Dependent Survival Pathways in DLBCLFOXO1 at baseline and following BCR crosslinking (Figure 3C).
Similar results were obtained in additional BCR-dependent, but
not BCR-independent, DLBCL cell lines (Figures S3A and
S3B). Consistent with these observations, R406 treatment selec-
tively induced expression of the FOXO1 target genes, BIM and
p27, in BCR-dependent, but not BCR-independent, DLBCL
cell lines (Figure 3D; Figure S3C).
SYK Inhibition Induces the Pro-Apoptotic BCL2 Family
Member, HRK
We next assessed the transcriptional profiles of R406-treated
BCR-dependent NF-kB-low DLBCLs for potential selective
apoptotic mechanisms. Differential analysis revealed selective
upregulation of the pro-apoptotic BCL2 family member, HRK,
in NF-kB-low DLBCLs following chemical SYK inhibition (Fig-
ure S4A). Although little is known about the role of HRK in
lymphoid cells, this BH3-only protein is specifically induced by
growth factor withdrawal in hematopoietic progenitors, leading
to cell death (Nakamura et al., 2008; Sanz et al., 2000). For this
reason, HRK induction was also evaluated by qRT-PCR in the
full panel of BCR-dependent and -independent DLBCL cell lines
treated with R406. Chemical SYK inhibition selectively induced
HRK in BCR-dependent NF-kB-low cell lines (DHL4, DHL6,830 Cancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc.and LY7); in contrast, HRK was not comparably upregulated in
BCR-dependent NF-kB-high cell lines (HBL-1 and U-2932) or
BCR-independent cell lines (K422, LY4, Toledo) (Figure 4A).
SYK depletion also selectively induced HRK expression
in BCR-dependent DLBCL cell lines with low baseline NF-kB
activity (Figure 4B).
Given the role of PI3K/AKT inmediating SYK/BCR survival sig-
nals in these DLBCLs (Figure 3B), we asked whether PI3K/AKT
also modulated HRK expression. In the BCR-dependent
NF-kB-low DLBCL lines, DHL4, DHL6, and LY7, chemical PI3K
inhibition (LY294002) was as effective as R406 treatment in
inducing HRK (Figure 4C). In each of these lines, expression of
mAKT abrogated HRK induction by R406 (Figure 4D). Therefore,
BCR signaling actively repressesHRK expression via a SYK- and
PI3K/AKT-mediated mechanism in BCR-dependent DLBCLs
with low baseline NF-kB.
We next assessed the role of HRK in the apoptosis of BCR-
dependent NF-kB-low DLBCLs using stable HRK knockdown
clones. In these HRK-depleted cells, R406 still inhibited proximal
components of the BCR signaling cascade (Figure S4B), but
failed to induce HRK (Figure 4E; Figure S4C). Most importantly,
R406 did not trigger the apoptosis of HRK-depleted DLBCLs
(Figure 4F; Figure S4D). These data directly implicate this
Figure 4. HRK Induction in DLBCL Cell Lines following SYK or PI3K Inhibition
(A) HRK transcript abundance in DLBCL cell lines following R406 treatment (24 hr) was determined by qRT-PCR.
(B) HRK expression in SYK-depleted DLBCL cell lines was assessed by qRT-PCR.
(C) HRK expression in the indicated cell lines following treatment with R406, LY294002, or vehicle for 24 hr assessed by qRT-PCR.
(D) HRK transcript abundance in DLBCL lines transduced with mAKT or pMIG, FACS-sorted, then treated with R406 or vehicle for 24 hr was analyzed by
qRT-PCR.
(E) DHL4 cells stably transduced with the indicated HRK siRNA or negative control siRNA (NC) were treated with R406 or vehicle for 24 hr and analyzed for HRK
transcript abundance by qRT-PCR.
(F) Apoptosis of DHL4 cells transduced with HRK siRNA or negative control siRNA (NC) and treated with vehicle or R406 for 72 hr was assessed by Annexin V/PI
staining.
(G and H) Viable DLBCL tumor cells isolated from cryopreserved primary patient samples were analyzed for cell surface Ig expression (G) or for HRK and BCL2A1
transcript abundance after treatment with R406 or vehicle for 24 hr by qRT-PCR (H). The p values for vehicle versus R406 (A and H), vehicle versus R406 or
LY29004 (C), NC versus shSYK (B), and pMIG +R406 versus mAKT +R406 (D) were determined with a one-sided Welch t test. ***p% 0.0001; **p% 0.001; *p%
0.01. Error bars represent the SD of three independent assays in a representative experiment.
See also Figure S4.
Cancer Cell
SYK/PI3K-Dependent Survival Pathways in DLBCLBH3-only protein in R406-induced apoptosis of NF-kB-low
DLBCLs and indicate that BCR-dependent survival signals
include active HRK repression.
Modulation of Survival Pathways in Primary DLBCLs
After defining distinct viability pathways in BCR-dependent
DLBCL cell lines with low or high baseline NF-kB activity, we
evaluated the same parameters in primary DLBCLs. Viable pri-
mary tumor cell suspensions were prepared and aliquots were
evaluated for cell-surface Ig or treated with vehicle or R406
and harvested for qRT-PCR analysis of HRK and BCL2A1 tran-scripts. We identified primary DLBCLs with high surface Ig
(P1–P4) or lower/undetectable surface Ig (P5 and P6) (Figure 4G),
as previously described (Chen et al., 2008), and assessed p65
nuclear staining in the associated P1-P4 fixed biopsy speci-
mens. Primary tumors P3 and P4 had significantly higher p65 nu-
clear staining than P1 and P2, indicating that P3 and P4 had
higher baseline NF-kB activity (Figures S4E and S2F). In primary
DLBCLs with higher baseline NF-kB activity (P3 and P4), R406
treatment significantly decreased BCL2A1 abundance; in
contrast, chemical SYK inhibition significantly increased HRK
abundance in DLBCLs with lower baseline p65 NF-kB activityCancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc. 831
Figure 5. SYK Expression following Chemi-
cal SYK Inhibition and FOXO1 Depletion
(A) SYK transcript abundance in DLBCL cell lines
was assessed by qRT-PCR following 24 hr of
treatment with R406 or vehicle.
(B) SYK transcript abundance in DLBCL cell lines
treated with R406 or vehicle for 24 hr following
transduction with indicated shRNA was analyzed
by qRT-PCR. The p values for vehicle versus R406
were determined with a one-sided Welch t test.
***p% 0.0001; **p% 0.001; *p% 0.01, #, p% 0.05.
Error bars represent the SD of three independent
assays in a representative experiment.
See also Figure S5.
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SYK/PI3K-Dependent Survival Pathways in DLBCL(P1 and P2) (Figure 4H). R406 treatment did not alter HRK or
BCL2A1 levels in primary DLBCLs with low or no surface Ig (P5
and P6; Figure 4H). Similar results were obtained in additional
viable primary tumor cell suspensions (Figures S4G and S4H).
Therefore, the distinct survival pathways defined in representa-
tive BCR-dependent DLBCL cell lines—SYK- and PI3K-modu-
lated NF-kB signaling or HRK repression—were also operative
in primary tumors.
Chemical SYK Inhibition Induces the FOXO1-Dependent
Transcriptional Upregulation of SYK
After characterizing distinct viability pathways in BCR-depen-
dent DLBCLs with low- or high-baseline NF-kB, we evaluated
the transcription profiles of all five R406-treated BCR-dependent
cell lines for potential common features. Pathway analyses
revealed transcriptional upregulation of proximal BCR signaling
pathway components including CD79B and SYK itself following
chemical SYK inhibition (Table S1; Figure S5A). We confirmed
the selective upregulation of SYK transcripts and protein in
BCR-dependent DLBCLs using the full panel of R406-treated
cell lines, qRT-PCR, and intracellular flow cytometry (Figure 5A;
Figure S5B). Although R406 treatment increased SYK transcript
and total protein abundance, phosphorylation of the down-
stream BCR signaling component BLNK was inhibited (Fig-
ure 5A; Figure S5B). The data suggest that the transcriptional
upregulation of certain proximal BCR signaling components
may be an attempted, but ineffective, compensatory response
to chemical SYK inhibition.
Chemical SYK inhibition increases the nuclear localization
of FOXO1 and FOXO1 activity (Figures 3C and 3D; Figures
S3A–S3C) and SYK is a recently described FOXO1 target832 Cancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc.(Ochiai et al., 2012). For these reasons,
we assessed the role of FOXO1 in SYK
expression. FOXO1 was depleted with
two independent shRNAs (Figure S5C)
and SYK transcript abundance was
assessed by qRT-PCR following vehicle
or R406 treatment. In the BCR-depen-
dent DLBCL lines (DHL4, LY7, and
HBL-1), the R406-associated induction
of SYK was abrogated by FOXO1
knockdown (Figure 5B). Therefore, in
BCR-dependent DLBCLs, the attemp-
ted compensatory response to chemicalSYK inhibition includes FOXO1-mediated transcriptional upre-
gulation of SYK.
SYK/BCR Inhibition Decreases the Abundance
of Cholesterol Biosynthesis Pathway Components
Pathway analyses of the five profiled BCR-dependent DLBCL
cell lines suggested that chemical SYK inhibition also had impor-
tant metabolic consequences. R406 treatment downregulated
multiple components of the cholesterol biosynthesis pathway,
including HMGCS1 (Figure 6A; Table S1; Reed et al., 2008). In
the full DLBCL cell line panel, chemical SYK inhibition selectively
decreased HMGCS1 protein abundance in BCR-dependent
DLBCLs but had no effect on BCR-independent tumors (Fig-
ure 6B). SYK depletion similarly decreased HMGCS1 expression
in representative BCR-dependent DLBCL cell lines with low or
high baseline NF-kB (Figure 6C).
Because cholesterol biosynthesis can be regulated by growth
factor- and hormone-induced PI3K/AKT signaling (Krycer et al.,
2010; Liu et al., 2009), we assessed the role of PI3K/AKT in
R406-mediated downregulation of HMGCS1. In a representative
BCR-dependent DLBCL cell line (DHL4), R406 and LY294002
treatment similarly decreased HMGCS1 expression (Figure 6D).
In addition, expression of mAKT completely abrogated R406-
mediated downregulation of HMGCS1 (Figure 6E). Together,
these data indicate that SYK/BCR inhibition modulates sterol
biosynthesis via PI3K/AKT.
Each of the SYK/BCR-responsive cholesterol pathway com-
ponents (Figure 6A) is a known target of SREBP, a PI3K/AKT-
dependent transcription factor and master regulator of choles-
terol biosynthesis (Krycer et al., 2010; Reed et al., 2008). PI3K/
AKT regulation of SREBP occurs at multiple levels, including
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SYK/PI3K-Dependent Survival Pathways in DLBCLFOXO1-mediated repression of SREBP transcripts (Liu et al.,
2009; Zhang et al., 2006) and mTORC1 and S6K1-dependent
processing of SREBP1 to its active nuclear form (Du¨vel et al.,
2010). In BCR-dependent DLBCLs, R406 treatment also
decreased the processing of SREBP1 (Figure S6A).
SYK Blockade Decreases Membrane Cholesterol
Content and Inhibits BCR Capping
To assess the functional consequences of SYK/PI3K-dependent
cholesterol biosynthesis in DLBCLs, we treated the full panel of
DLBCL cell lines with R406 and evaluated cholesterol membrane
content. Following R406 or vehicle treatment, DLBCL cell lines
were stained with filipin, which forms a fluorescent complex
with cholesterol (Gimpl and Gehrig-Burger, 2007; Karnell et al.,
2005). Then, filipin flow cytometry was used to quantify and visu-
alize the cellular distribution of cholesterol. SYK/BCR inhibition
clearly decreased cholesterol membrane content in BCR-
dependent DLBCLs but had no effect on BCR-independent
DLBCLs (Figure 6F).
To determine the functional consequences of decreased
cholesterol membrane content, we characterized ligand (anti-
IgG)-induced BCR redistribution in filipin-stained DLBCLs
(Karnell et al., 2005). In BCR-dependent NF-kB-low DLBCLs,
filipin-stained cholesterol-enriched membrane domains colocal-
ized with the BCR following anti-Ig induced capping (Fig-
ure 6G, +BCR). In contrast, BCR capping and the colocalization
of BCR and filipin/cholesterol were markedly decreased
following R406 treatment (Figure 6G, +R406/+BCR). Similar
results were obtained in two high-NF-kB cell lines, HBL-1 and
U-2932 (Figure S6B). These studies indicate that in BCR-depen-
dent DLBCLs, chemical SYK inhibition perturbs the integrity of
cholesterol-rich lipid rafts and the association of BCR clusters
with these regions.
Genetic Bases for Enhanced BCR Signaling
in BCR-Dependent DLBCLs
After defining a role for SYK and PI3K/AKT in the survival of BCR-
dependent DLBCL cell lines and primary tumors, we assessed
potential genetic bases for the enhanced BCR signaling. Using
a well-annotated series of primary DLBCLs with available tran-
scription profiles and high-resolution copy number data (Monti
et al., 2012), we evaluated proximal BCR signaling components
including SYK and the negative regulator of PI3K/AKT signaling,
PTEN. In this primary DLBCL series, there were recurrent single
copy gains of SYK and monoallelic chromosome 10q23/PTEN
deletions with associated highly significant changes in transcript
abundance (Figure 7A; Figures S7A and S7B; Table S2). These
genetic alterations were largely mutually exclusive and signifi-
cantly more abundant in primary DLBCLs defined as ‘‘BCR-
type’’ by transcriptional profiling (Figure 7B; Figures S7A and
S7B). Consistent with these findings, PTEN depletion protected
one of the three BCR-dependent DLBCL cell lines from chemical
SYK inhibition (Figures S7C and S7D).
DISCUSSION
In this study, we characterize distinct SYK/PI3K/AKT-dependent
BCR viability pathways in DLBCL cell lines and primary
tumors with high- and low-baseline NF-kB activity and defineSYK/PI3K/AKT-dependent repression of the pro-apoptotic
HRK protein as an important survival mechanism in BCR-depen-
dent NF-kB low DLBCLs (Figure 8A). In addition, we identify
SYK/PI3K/AKT-dependent cholesterol biosynthesis as a feed-
forward mechanism of preserving the integrity of BCRs in lipid
rafts in DLBCLs with low- or high-baseline NF-kB (Figure 8B).
Consistent with the roles of SYK and PI3K/AKT as important
mediators of BCR survival signals in primary DLBCLs, we also
identify SYK amplification and PTEN deletion as selective and
largely mutually exclusive genetic alterations in ‘‘BCR’’-type
tumors.
Our studies highlight the important role of PI3/AKT in the BCR-
dependent survival of DLBCLs with high- or low-baseline NF-kB
activity. In DLBCLs with high-baseline NF-kB activity, genetic
alterations of multiple NF-kB pathway components have been
described (Compagno et al., 2009; Lenz et al., 2008; Ngo
et al., 2011) and additional CD79A and CD79B mutations have
been reported (Davis et al., 2010). However, the sensitivity of
DLBCLs with high baseline NF-kB activity to inhibition of
upstream BCR signals was incompletely defined. In this study,
chemical SYK blockade and molecular SYK depletion
decreased NF-kB activity and target gene expression in DLBCL
primary tumors and cell lines with high-baseline NF-kB, including
lines with wild-type CARD11 and either wild-type CD79B
(U-2932) or CD79B missense mutations (HBL-1) (Davis et al.,
2010). Chemical PI3K inhibition had similar effects. Taken
together, these studies indicate that DLBCLs with high-baseline
NF-kB activity remain sensitive to inhibition of proximal SYK/
PI3K signals.
In BCR-dependent DLBCL cell lines and primary tumors with
low-baseline NF-kB activity, both the chemical inhibition and
molecular depletion of SYK induced the pro-apoptotic HRK pro-
tein via a PI3K/AKT-dependent mechanism. HRK depletion
abrogated R406-induced cytotoxicity in these cells. These data
highlight the previously unappreciated role of this BH3-only pro-
tein in DLBCL apoptosis and indicate that BCR-dependent sur-
vival signals include active HRK repression. These observations
are consistent with earlier studies in which HRK was actively
repressed at baseline and specifically induced following growth
factor withdrawal in hematopoietic progenitors and neuronal
cells (Nakamura et al., 2008; Sanz et al., 2001; Towers et al.,
2009). In these experimental settings, HRK induction led to rapid
cell death, as in our study. Additional genetic bases of HRK
repression, such as hypermethylation and allelic loss, have
been described in certain cancers including primary central ner-
vous system lymphomas (Nakamura et al., 2008).
In our studies, molecular SYK depletion phenocopies chemi-
cal SYK inhibition in a panel of BCR-dependent and -indepen-
dent DLBCL cell lines. Similar results were recently described
in an overlapping series of DLBCL cell lines (Cheng et al.,
2011). In BCR-dependent DLBCLs, R406 treatment induces
FOXO1-mediated transcriptional upregulation of SYK, indicating
that SYK is a tightly regulated component of the BCR signaling
and survival pathway.
Chemical SYK inhibition also selectively decreased multiple
components of the cholesterol biosynthesis pathway. SYK/
BCR inhibition modulated cholesterol biosynthesis via PI3K/
AKT and implicated the PI3K/AKT-dependent transcription
factor and master regulator of cholesterol biosynthesis, SREBPCancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc. 833
(legend on next page)
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Figure 7. SYK and PTEN Copy Number Alterations in Primary
DLBCLs
(A)SYK andPTEN copy numbers were assessed and associated with SYK and
PTEN transcript levels in primary DLBCLs (n = 169). SYK and PTEN copy
numbers and transcript abundance were derived from (Monti et al., 2012). The
p values were determined with a one-sided t test. Box plot (median, line; 25%
and 75% quartile, box; whiskers, maximum to minimum).
(B) Relative frequency of SYKAMP and PTENDEL was assessed in transcrip-
tionally defined ‘‘BCR’’ type versus other primary DLBCLs (n = 147; tumors
with high confidence classification into CCC categories) (Monti et al., 2012).
The p values were determined with a two-sided Fisher exact test.
See also Figure S7 and Table S2.
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Porstmann et al., 2008). In BCR-dependent DLBCLs, R406-
treatment also decreased cholesterol membrane content and
perturbed the integrity of cholesterol-rich lipid rafts and the asso-
ciation of BCR clusters with these membrane domains (Gupta
and DeFranco, 2007). Therefore, in addition to directly modu-
lating downstream apoptotic pathways, chemical SYK inhibition
alters cholesterol biosynthesis, with associated adverse conse-
quences for cell membrane integrity and the assembly of BCR
clusters.
The modulation of cholesterol biosynthesis by SYK is of addi-
tional interest given the recently described distinct metabolic
profiles in BCR-dependent and BCR-independent/OxPhos
DLBCLs (Caro et al., 2012). In BCR-dependent DLBCLs, SYK
signaling limits the mitochondrial oxidation of fatty acids (CaroFigure 6. Cholesterol Biosynthesis in DLBCLs following SYK or PI3K I
(A) Components of the cholesterol biosynthesis pathway modulated by R406 tre
(B) HMGCS1 protein abundance in R406- or vehicle-treated DLBCL cell lines wa
(C) HMGCS1 transcript abundance in DLBCL cell lines transduced with indicated
determined with a one-sided Welch t test. ***p% 0.0001; *p% 0.01; #, p% 0.02
experiment.
(D) HMGCS1 protein abundance in DHL4 following treatment with R406 or LY29
(E) HMGCS1 and p-AKT(S473) in parental DHL4 cells and DHL4 cells transduced
b-actin, loading control.
(F) Membrane cholesterol content in DLBCL cell lines treated with vehicle (black)
filipin flow cytometry. Unstained controls in gray. (G) DHL4 and LY7 cells were in
with anti-Ig for 10 min (+BCR). The cells were fixed, stained with filipin (green)
microscopy. Scale bar represents 25 mm.
See also Figure S6.et al., 2012), which likely ensures the availability of metabolic
intermediates such as acetyl CoA for HMGCS1-mediated
cholesterol biosynthesis. In comparison, acetyl-CoA derived
from fatty acid enters the tricarboxylic acid cycle in BCR-inde-
pendent/OxPhos DLBCLs that exhibit increased mitochondrial
fatty acid oxidation (Caro et al., 2012). These findings further
define molecular subsets of DLBCLs with distinct metabolic
features that are linked to the functional state of upstream
BCR signaling components.
We previously found that BCR-dependent DLBCL cell lines
and primary tumors with low baseline NF-kB activity also
responded to SYK/BCR inhibition (Chen et al., 2008). However,
it was unclear whether these DLBCLs had uncharacterized
genetic alterations of BCR signaling pathway components or
preserved reliance on physiologic ‘‘tonic’’ BCR survival signals.
In the current analysis of an extensive series of newly diagnosed
primary DLBCLs, SYK amplification and PTEN deletion were
identified as largelymutually exclusive genetic alterations in tran-
scriptionally-defined ‘‘BCR-type’’ DLBCLs. Given the role of
PI3K/AKT in SYK/BCR-dependent survival signals in DLBCLs,
these data suggest additional genetic bases for increased BCR
pathway activity in these tumors.
Taken together, these functional and genetic studies provide a
framework for analyzing targeted inhibition of SYK, PI3K and
additional proximal components of the BCR signaling pathway
in BCR-dependent DLBCLs and set the stage for further clinical
analysis of promising candidate inhibitors.EXPERIMENTAL PROCEDURES
Cell lines and culture conditions are in Supplemental Experimental Proce-
dures. BCR crosslinking was performed as previously described (Chen
et al., 2008).Primary Tumor Specimens
Cryopreserved viable primary DLBCL samples were obtained according to
Institutional Review Board (IRB)-approved protocols from Mayo Clinic, Brig-
ham and Women’s Hospital and the Dana-Farber Cancer Institute. These
anonymous primary tumor specimens were considered discarded tissues
that did not require informed consent.Chemical Inhibition with R406 or LY294002
For immediate inhibition, cells were incubated with 1 mMR406 or vehicle alone
(in PBS) in a 37C water bath for 1 hr. For long-term inhibition, compounds
(R406 [1 mM or 4 mM] or LY29004 [10 mM]) were added to cell culture medium
at the final indicated concentration and cells were maintained in a 37Cnhibition
atment (red) were identified by pathway analyses of the profiled cell lines.
s assessed by immunoblotting. b-actin, loading control.
shRNA was assessed by qRT-PCR. The p values for NC versus shSYK were
. Error bars represent the SD of three independent assays in a representative
4002 was assessed by immunoblotting. b-actin, loading control.
with mAKT or pMIG and treated with R406 was determined by immunoblotting.
or R406 (red) for 2 days and fixed with 4% paraformaldehyde was assessed by
cubated with vehicle or R406 for 48 hr and left untreated (BCR) or stimulated
and the indicated Cy3-conjugated anti-Ig (red), and assessed with confocal
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Figure 8. SYK and PI3K-Dependent Viability Pathways in DLBCLs
(A) SYK- and PI3K-dependent anti-apoptotic pathways in BCR-dependent
DLBCLs. In BCR-dependent DLBCLswith low-baseline NF-kB activity, SYK or
PI3K inhibition relieve BCR-dependent repression of the pro-apoptotic BH3
molecule, HRK. In BCR-dependent DLBCLswith high-baseline NF-kB activity,
SYK or PI3K inhibition decreases the abundance of the anti-apoptotic NF-kB
targets such as BCL2A1.
(B) SYK- and PI3K-dependent regulation of cholesterol biosynthesis and
associated integrity of BCRs in lipid rafts in BCR-dependent DLBCLs.
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SYK/PI3K-Dependent Survival Pathways in DLBCLincubator for 24 or 48 hr. Details are provided in the Supplemental Experi-
mental Procedures.
RNA Interference
Cells were infected with lentivirus containing either negative control (vector
pLKO.1-emptyT, TRCN0000208001, Broad Institute, MA) or specific SYK,
FOXO1, or PTEN shRNAs, puromycin-selected for 48 hr and analyzed for
knockdown efficacy and cellular proliferation thereafter. HRK-specific oligonu-
cleotides or negative control (NC) oligonucleotides were ligated into the linear-
ized pSIREN-RetroQ retroviral vector (Clontech, Mountain View, CA). After
retroviral infection and puromycin selection, cells were subcloned by limiting
dilution. Selected subclones were treated with R406 or vehicle and efficient
HRK knockdown (>75%) was confirmed by qRT-PCR. Details are provided
in the Supplemental Experimental Procedures.
Intracellular Flow
Intracellular flowcytometry for p-SYK352, p-BLNK84, total SYK, andPTEN (BD
Biosciences, CA) was performed as previously described (Chen et al., 2008).
Immunofluorescence
DLBCL cell lines that were treated with vehicle or R406, with or without subse-
quent BCR crosslinking, were formalin-fixed, paraffin-embedded, and
analyzed for FOXO1 expression and subcellular localization using a rabbit
monoclonal anti-FOXO1 antibody (Cell Signaling Technology) and anti-rabbit
Cy3-conjugated antibody solution (Invitrogen). The FOXO1-Cy3 stained slides
were scanned with a digital FACS imaging system (TissueGnostics, Vienna,
Austria) and analyzed with TissueQuest (Tissuegnostics, Vienna, Austria).
Details are provided in the Supplemental Experimental Procedures.
Analyses of cellular proliferation and apoptosis, immunoblotting, qRT-PCR,
transcriptional profiling and transduction with mAKT are provided in the Sup-
plemental Experimental Procedures.
NF-kB Activity Assay
DLBCL cell lines that were treated with vehicle, R406 or LY294002 were har-
vested, nuclear extracts were prepared and NF-kB activity was assessed
using a TransAM NF-kB family kit and the manufacturer’s positive control
(ActiveMotif, Carlsbad, CA). This colorimetric assay detects binding of nuclear
(activated) p65 (RELA) to immobilized NF-kB target consensus oligonucleotide
sequences as described (Feuerhake et al., 2005).836 Cancer Cell 23, 826–838, June 10, 2013 ª2013 Elsevier Inc.Filipin Staining
After fixation in 4% paraformaldehyde (1 hr at room temperature) and washes
in PBS, cells were incubated in 1 ml PBS-glycine (1.5 mg/ml; 10 min at room
temperature) to quench the paraformaldehyde. Thereafter, cells were stained
with 1ml PBS containing 50 mg/ml filipin (1 hr at room temperature) and directly
analyzed on a flow cytometer (FACS Canto II, BD Biosciences).
Confocal Microscopy
DLBCL lines (5 3 106 cells) treated with 1 mM R406 or vehicle were harvested
and resuspended in 0.5 ml PBS and incubated at 37C water bath for 20 min.
Thereafter, cells were stimulated with Cy3-conjugated AffiniPure F(ab0)2 Frag-
ment Goat anti-human IgG or IgM for 10 min, and the reaction was stopped by
the addition of cold PBS/0.1% bovine serum albumin/0.02% azide. The cells
were fixed in 4% paraformaldehyde/0.1% glutaraldehyde, followed by
washing and resuspension in 0.5 mg/ml sodium borohydride to stop fixation.
For untreated DLBCL lines that were not BCR crosslinked, cells were fixed
with paraformaldehyde before staining with Cy3-conjugated AffiniPure
F(ab0)2 fragment rabbit anti-goat IgG or IgM. Thereafter, all samples were incu-
bated in PBS containing 50 mg/ml filipin for 1 hr. The cells were adhered to
glass slides by centrifugation at 1,200 rpmusing cytospin centrifuge (Shandon)
andmounted with Prolong Gold anti-fade agent (Invitrogen, Oregon). The cells
were visualized using Leica SP53 confocal microscope. Images were
captured and analyzed using LAS AF software (Leica Microsystems CMS
GmbH).
Analysis of SYK and PTEN Somatic Copy Number Changes and
Transcript Abundance in Primary DLBCLs
SYK and PTEN loci copy numbers were assessed and associated with respec-
tive SYK and PTEN transcript levels in 169 newly diagnosed DLBCLs (HD-SNP
array data and transcriptional profiles fromMonti et al., 2012; Gene Expression
Omnibus accession number GSE34171). In tumors with SYKAMP versus
SYKnonAMP or PTENDEL versus PTENnonDEL, respective SYK or PTEN transcript
levels were visualized with a box plot and evaluated with a Fisher exact test
(Dawson-Saunders and Trapp, 1994). The distribution of SYK and PTEN
copy number alterations in BCR versus Other CCC categories was evaluated
with a Fisher exact test. Visualization and statistical testing were performed
using GraphPad Prism version 5.04 for Windows, GraphPad Software, San
Diego, CA, http://www.graphpad.com.
ACCESSION NUMBER
The Gene Expression Omnibus accession number for the gene expression
data reported in this paper is GSE43510.
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